SARS-CoV-2 anti-spike protein IgG concentration, ELU / mLD day 28 after the third dose23 325 (20 030–27 162); 6625 317 (20 996–30 528); 6620 502 (16 473–25 517); 3521,980 (16,476–29,324); 3326 982 (22 056–33 008); 3129 161 (23 093–36 823); 33Day 0 of the fourth dose3049 (2550–3646); 663469 (2730–4407); 662532 (1974–3247); 352571 (1874–3527); 343761 (2959–4780); 314769 (3421–6648); 32 Day 14 after the fourth dose37 460 (31 996–43 857); 6554 936 (46 826–64 452); 6733 316 (26 942–41 198); 3552 080 (41 163–65 894); 3442 949 (34 148–54 019); 3058 043 (46 693–72 150); 33 Change in times (day 14 after the fourth dose versus day 28 after the third dose) 1 · 59 (1 · 41–1 · 78); 652 · 19 (1 · 90–2 · 52); 661 · 62 (1 · 35–1 · 95); 352 · 41 (1 · 90–3 · 05); 331 · 54 (1 · 35–1 · 76); 301 · 99 (1 · 71–2 · 31); 33 Change of times (day 14 after the fourth dose versus day 0 of the fourth dose) 12 · 19 (10 · 37–14 · 32); 6515 · 90 (12 · 92–19 · 58); 6613 · 16 (10 · 24–16 · 91); 3520 · 26 (15 · 09–27 · 21); 3411 · 14 (9 · 21–13 · 47); 3012 · 30 (9 · 39–16 · 11); 32Cell response (wild type), spotting cells at 106 PBMC *
Due to logistical reasons, only 50% of the study sites collected samples from cellular immunology (close to an external laboratory) in the main COV-BOOST study; samples of cellular immunology after the fourth dose were collected in the immunological group.
Day 28 after the third dose96 · 03 (65 · 68–140 · 42; 35111 · 19 (75 · 87–162 · 95); 33133 · 33 (81 · 31–218 · 62); 19113 · 40 (57 · 93 – 221 · 98); 1765 · 04 (37 · 76–112 · 03); 16108 · 90 (75 · 81–156 · 43); 16Day 0 of the fourth dose19 · 32 (10 · 99–33 · 97); 3635 · 32 (20 · 66–60 · 40); 3418 · 85 (8 · 31–42 · 77); 2042 · 13 (18 · 58–95 · 51); 1619 · 93 (9 · 14–43 · 48); 1630 · 20 (14 · 71–62 · 02); 18Day 14 after the fourth dose112 · 64 (80 · 61–157 · 38); 20236 · 95 (146 · 04–384 · 48); 20141 · 99 (92 · 57) –217 · 80 () 11232 · 98 (116 · 70–465 · 12); 1184 · 87 (51 · 94–138 · 66); 9241 · 91 (118 · 79–492 · 64); 9 Folding change day 14 after the fourth dose versus day 28 after the third dose) 1 · 10 (0 · 72–1 · 70); 181 · 69 (1 · 22–2 · 34); 191 · 09 (0 · 63–1 · 89) ; 101 · 16 (0 · 79–1 · 70); 111 · 12 (0 · 54–2 · 31); 82 · 83 (2 · 02–3 · 96); 8 changes (day 14 after the fourth dose against day 0 of the fourth dose) 7 · 32 (3 · 24–16 · 54); 196 · 22 (3 · 90–9 · 92); 2011 · 07 (4 · 21–29 · 12); 116 · 34 · 89–13 · 92 (114 · 14 (1 · 04–16 · 54); 86 · 08 (3 · 86–9 · 56); 9Cell response (beta), 106 PBMC blotting cells *
Due to logistical reasons, only 50% of the study sites collected samples from cellular immunology (close to an external laboratory) in the main COV-BOOST study; samples of cellular immunology after the fourth dose were collected in the immunological group.
Day 28 after the third dose98 · 34 (72 · 11–134 · 10); 35108 · 85 (76 · 90–154 · 07); 33132 · 70 (87 · 79–200 · 59); 19120 · 52 (65 · 57–221 · 54); 1768 · 89 (45 · 39–104 · 57); 1697 · 69 (70 · 62–135 · 12); 16 Day 0 of the fourth dose18 · 53 (10 · 60–32 · 37); 3628 · 35 (15 · 40–52 · 19); 3416 · 71 (7 · 50–37 · 22); 2037 · 69 (16 · 24–87 · 46); 1621 · 07 (9 · 64–46 · 06); n = 1622 · 01 (9 · 11–53 · 20); 18 Day 14 after the fourth dose85 · 55 (54 · 11–135 · 28); 20245 · 84 (158 · 84–380 · 50); 2096 · 25 (55 · 85–165 · 86); 11256 · 42 (142 · 42–461 · 65); 1174 · 08 (33 · 34–164 · 60); 9233 · 50 (117 · 10–465 · 64); 9 Change in times (day 14 after the fourth dose versus day 28 after the third dose) 0.98 (0.64-1.50); 181 · 96 (1 · 36–2 · 82); 190 · 93 (0 · 54–1 · 61); 101 · 30 (0 · 91–1 · 87); 111 · 03 (0 · 50–2 · 12); 83 · 45 (2 · 10–5 · 69); 8 Change of times (day 14 after the fourth dose versus day 0 of the fourth dose) 5 · 47 (2 · 30–13 · 02); 198 · 48 (4 · 72–15 · 22); 207 · 63 (2 · 51–23 · 17); 118 · 98 (4 · 19–19 · 23); 113 · 46 (0 · 85–14 · 08); 87 · 91 (3 · 04–20 · 56); 9Cell response (delta), 106 PBMC blotting cells *
Due to logistical reasons, only 50% of the study sites collected samples from cellular immunology (close to an external laboratory) in the main COV-BOOST study; samples of cellular immunology after the fourth dose were collected in the immunological group.
Day 28 after the third dose92 · 48 (66 · 90–127 · 85); 35104 · 34 (72 · 95–149 · 24); 33130 · 31 (92 · 00–184 · 58); 19114 · 49 (61 · 51–213 · 11); 1761 · 55 (36 · 64–103 · 38); 1694 · 54 (66 · 74–133 · 91); 16 Day 0 of the fourth dose16 · 40 (9 · 38–28 · 68); 3635 · 93 (20 · 29–63 · 62); 3418 · 39 (8 · 68–38 · 95); 2041 · 93 (17 · 99–97 · 78); 1614 · 22 (6 · 02–33 · 58); 1631 · 31 (14 · 19–69 · 08); 18 Day 14 after the fourth dose94 · 20 (66 · 92–132 · 60); 20239 · 62 (155 · 19–369 · 97); 20108 · 24 (69 · 20–169 · 28); 11244 · 67 (141 · 79–422 · 20); 1179 · 49 (46 · 55–135 · 72); 9233 · 59 (111 · 99–487 · 24); 9 Change of times (day 14 after the fourth dose versus day 28 after the third dose) 1 · 00 (0 · 68–1 · 49); 182 · 03 (1 · 39–2 · 97); 190 · 88 (0 · 56–1 · 38); 101 · 28 (0 · 89–1 · 84); 111 · 19 (0 · 59–2 · 40); 83 · 85 (2 · 39–6 · 21); 8 Change of times (day 14 after the fourth dose versus day 0 of the fourth dose) 7 · 57 (3 · 32–17 · 25); 196 · 35 (3 · 51–11 · 49); 209 · 37 (3 · 56–24 · 67); 116 · 62 (2 · 87–15 · 25); 115 · 64 (1 · 27–25 · 06); 86 · 04 (2 · 48–14 · 68); 9
Add Comment